NASDAQ:NAGE Niagen Bioscience Q3 2025 Earnings Report $3.04 +0.05 (+1.67%) Closing price 09/21/2026 04:00 PM EasternExtended Trading$3.04 0.00 (0.00%) As of 04:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Niagen Bioscience EPS ResultsActual EPS$0.05Consensus EPS $0.02Beat/MissBeat by +$0.03One Year Ago EPSN/ANiagen Bioscience Revenue ResultsActual Revenue$33.99 millionExpected Revenue$31.30 millionBeat/MissBeat by +$2.69 millionYoY Revenue GrowthN/ANiagen Bioscience Announcement DetailsQuarterQ3 2025Date11/4/2025TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Niagen Bioscience Earnings HeadlinesNewly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with ...September 21 at 3:20 PM | marketscreener.comMNewly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (NR) Improves Pregnancy OutcomesSeptember 21 at 8:32 AM | businesswire.comElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the largest markets in the world. James Altucher, who previously flagged Nvidia in 2008 and Bitcoin in 2013, says the filing could rival Tesla, SpaceX and xAI combined. Few investors know this filing exists, but that is expected to change quickly. | Paradigm Press (Ad)Analysts Offer Insights on Consumer Goods Companies: Celsius Holdings (CELH) and Niagen Bioscience (NAGE)September 19 at 12:16 PM | theglobeandmail.comNiagen Bioscience, Inc. (NAGE)September 18, 2026 | finance.yahoo.comNiagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business GrowthSeptember 17, 2026 | businesswire.comSee More Niagen Bioscience Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Niagen Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Niagen Bioscience and other key companies, straight to your email. Email Address About Niagen BioscienceNiagen Bioscience (NASDAQ:NAGE) is a bioscience company focused on developing and commercializing products designed to support healthy aging and cellular energy metabolism. The company’s research centers on nicotinamide riboside (NR), a form of vitamin B3 and precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme involved in numerous cellular processes. The company markets its proprietary NIAGEN branded NR ingredient to supplement manufacturers and sells consumer products under the Tru Niagen brand. Tru Niagen products are available in dietary supplement formulations intended to support NAD+ levels and cellular health. Niagen Bioscience also maintains intellectual property and conducts research related to NR and NAD+ biology. The company was formerly known as ChromaDex Corporation and adopted the Niagen Bioscience name as part of its focus on the NIAGEN platform. Its products are marketed through direct-to-consumer and commercial channels in the United States and internationally. The company is led by Chief Executive Officer Robert N. Fried.View Niagen Bioscience ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 5 Dividend Stocks That Combine Income, Earnings Growth, and Wall Street SupportCoach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback3 Retail Stocks Getting Crushed and the Long-Dated Options Trade on Each One3 Surging Stocks That Don’t Need the AI Boom to Keep WinningJ.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. Housing3 Software Stocks Rebounding as AI Fears Give Way to Growth Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
